The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: A meta-analysis.
用户v6VaaO-afFI8
1个月前
97
10
已关闭
DOI: 10.1200/jco.2017.35.15_suppl.e23075
文献链接: http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.e23075
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Tengfei Zhang; Ruitai Fan; Ni Shi; Wang Ma

